Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
Short, Medium and Long-term Effects of Pulmonary Rehabilitation in Dyspnea, Health Status, Anxiety and Depression Symptoms, Functional Status and Postural Control and Its Relationship With Morbimortality in Patients With COPD
NCT number | NCT03692793 |
Other study ID # | NuReabPRP |
Secondary ID | |
Status | Terminated |
Phase | N/A |
First received | |
Last updated | |
Start date | April 1, 2013 |
Est. completion date | March 31, 2020 |
Verified date | April 2021 |
Source | University of the State of Santa Catarina |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: The pulmonary rehabilitation effects on various outcomes of COPD are well known. However, they may be lost over time due to poor adherence to therapy with absence of regular exercise maintenance in long term, disease progression, comorbidities, falls incidence and higher exacerbations frequency. Currently, the main focus is to make the patient more active and ensure the benefits maintenance. However, few studies have been concerned with the aim of to investigate the long-term effect of this intervention and the relationship of the change promoted in important outcomes of the disease with its morbidity and mortality. Design: Non-controlled clinical trial, prospective and longitudinal. Setting: Outpatient pulmonary rehabilitation program in Florianopolis, Brazil Subjects: Patients with COPD (GOLD II-IV). Interventions: Pulmonary rehabilitation program (PRP) based on physical training, conducted over 24 sessions supervised, three times a week, including aerobic training in treadmill and resistance training for upper and lower limbs. Main measures: Before, post-PRP, 6 months post-PRP and 12 months post-PRP will be measured Spirometry or Total Body Plethysmography, Triaxial Accelerometry by Dynaport Activity Monitor, Glittre ADL-Test to evaluated functional capacity and functional performance, Six-Minute Walk Test distance on tracks of 20 and 30 meters, muscle oxygenation variables by NIRS PortaLite®, force platform NeuroCom® SMART Equitest®, Timed Up and Go Test, Berg Balance Scale, Activities-specific Balance Confidence, Falls Efficacy Scale - International - Brasil, London Chest Activity of Daily Living score, Modified Medical Research Council score, Saint George Respiratory Questionnaire score, COPD Assessment Test score and Hospital Anxiety and Depression Scale, Behavioural Regulation in Exercise Questionnaire-2, Basic Psychological Needs in Exercise Scale, General self-efficacy scale, COPD self-efficacy scale, Pulmonary Rehabilitation Adapted Index of Self-Efficacy. The death cases and numbers of exacerbations and hospitalizations will be measured by monthly phone calls after PRP.
Status | Terminated |
Enrollment | 40 |
Est. completion date | March 31, 2020 |
Est. primary completion date | March 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion Criteria: - Clinical diagnosis of COPD confirmed by spirometry (COPD GOLD stages II, III and IV); - Clinical stability in the past four weeks. Exclusion Criteria: - Hospital admission in the past 12 weeks; - Any other disease or health condition that could compromise the test´s execution or physical training; - Participation in pulmonary rehabilitation program completed in the last six months; - Current smoking or its cessation in less than six months; - Interruption of pulmonary rehabilitation program for any reason; - Any change in symptoms during the study protocol assessments. |
Country | Name | City | State |
---|---|---|---|
Brazil | Núcleo de Assistência, Ensino e Pesquisa em Reabilitação Pulmonar | Florianópolis | SC |
Lead Sponsor | Collaborator |
---|---|
University of the State of Santa Catarina |
Brazil,
Botega NJ, Bio MR, Zomignani MA, Garcia C Jr, Pereira WA. [Mood disorders among inpatients in ambulatory and validation of the anxiety and depression scale HAD]. Rev Saude Publica. 1995 Oct;29(5):355-63. Portuguese. — View Citation
Camargos FF, Dias RC, Dias JM, Freire MT. Cross-cultural adaptation and evaluation of the psychometric properties of the Falls Efficacy Scale-International Among Elderly Brazilians (FES-I-BRAZIL). Rev Bras Fisioter. 2010 May-Jun;14(3):237-43. English, Portuguese. — View Citation
Carpes MF, Mayer AF, Simon KM, Jardim JR, Garrod R. The Brazilian Portuguese version of the London Chest Activity of Daily Living scale for use in patients with chronic obstructive pulmonary disease. J Bras Pneumol. 2008 Mar;34(3):143-51. English, Portuguese. — View Citation
Demeyer H, Burtin C, Van Remoortel H, Hornikx M, Langer D, Decramer M, Gosselink R, Janssens W, Troosters T. Standardizing the analysis of physical activity in patients with COPD following a pulmonary rehabilitation program. Chest. 2014 Aug;146(2):318-327. doi: 10.1378/chest.13-1968. — View Citation
Garrod R, Bestall JC, Paul EA, Wedzicha JA, Jones PW. Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living scale (LCADL). Respir Med. 2000 Jun;94(6):589-96. — View Citation
Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, McCormack MC, Carlin BW, Sciurba FC, Pitta F, Wanger J, MacIntyre N, Kaminsky DA, Culver BH, Revill SM, Hernandes NA, Andrianopoulos V, Camillo CA, Mitchell KE, Lee AL, Hill CJ, Singh SJ. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014 Dec;44(6):1428-46. doi: 10.1183/09031936.00150314. Epub 2014 Oct 30. Review. — View Citation
Jácome C, Cruz J, Oliveira A, Marques A. Validity, Reliability, and Ability to Identify Fall Status of the Berg Balance Scale, BESTest, Mini-BESTest, and Brief-BESTest in Patients With COPD. Phys Ther. 2016 Nov;96(11):1807-1815. Epub 2016 Apr 14. — View Citation
Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009 Sep;34(3):648-54. doi: 10.1183/09031936.00102509. — View Citation
Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991 Sep;85 Suppl B:25-31; discussion 33-7. — View Citation
Kovelis D, Segretti NO, Probst VS, Lareau SC, Brunetto AF, Pitta F. Validation of the Modified Pulmonary Functional Status and Dyspnea Questionnaire and the Medical Research Council scale for use in Brazilian patients with chronic obstructive pulmonary disease. J Bras Pneumol. 2008 Dec;34(12):1008-18. English, Portuguese. — View Citation
MARKLAND, D.; TOBIN, V. A. A modification to the Behavioural Regulation in Exercise Questionnaire to include an assessment of amotivation. Journal of Sport and Exercise Psychology, v. 26, n. 2, p. 191-96, 2004.
Marques AP, Mendes YC, Taddei U, Pereira CA, Assumpção A. Brazilian-Portuguese translation and cross cultural adaptation of the activities-specific balance confidence (ABC) scale. Braz J Phys Ther. 2013 Mar-Apr;17(2):170-8. doi: 10.1590/S1413-35552012005000072. — View Citation
Mesquita R, Wilke S, Smid DE, Janssen DJ, Franssen FM, Probst VS, Wouters EF, Muris JW, Pitta F, Spruit MA. Measurement properties of the Timed Up & Go test in patients with COPD. Chron Respir Dis. 2016 Nov;13(4):344-352. doi: 10.1177/1479972316647178. Epub 2016 Jul 8. — View Citation
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. — View Citation
Pereira CA, Sato T, Rodrigues SC. New reference values for forced spirometry in white adults in Brazil. J Bras Pneumol. 2007 Jul-Aug;33(4):397-406. English, Portuguese. — View Citation
Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Quantifying physical activity in daily life with questionnaires and motion sensors in COPD. Eur Respir J. 2006 May;27(5):1040-55. Review. — View Citation
SCHWARZER, R.; JERUSALÉM, M. Generalized Self-Efficacy scale. In: WEINMAN, J. e WRIGHT, M. J. Measures in health psychology: A user's portfolio. . Windsor, UK: NFER-NELSON, 1995.
Silva PN, Jardim JR, Costa e Souza GM, Hyland ME, Nascimento OA. Cultural adaptation and reproducibility of the Breathing Problems Questionnaire for use in patients with COPD in Brazil. J Bras Pneumol. 2012 May-Jun;38(3):339-45. English, Portuguese. Erratum in: J Bras Pneumol. 2012 Jul-Aug;38(4):538. — View Citation
Skumlien S, Hagelund T, Bjørtuft O, Ryg MS. A field test of functional status as performance of activities of daily living in COPD patients. Respir Med. 2006 Feb;100(2):316-23. Epub 2005 Jun 6. — View Citation
Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, Hill K, Holland AE, Lareau SC, Man WD, Pitta F, Sewell L, Raskin J, Bourbeau J, Crouch R, Franssen FM, Casaburi R, Vercoulen JH, Vogiatzis I, Gosselink R, Clini EM, Effing TW, Maltais F, van der Palen J, Troosters T, Janssen DJ, Collins E, Garcia-Aymerich J, Brooks D, Fahy BF, Puhan MA, Hoogendoorn M, Garrod R, Schols AM, Carlin B, Benzo R, Meek P, Morgan M, Rutten-van Mölken MP, Ries AL, Make B, Goldstein RS, Dowson CA, Brozek JL, Donner CF, Wouters EF; ATS/ERS Task Force on Pulmonary Rehabilitation. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013 Oct 15;188(8):e13-64. doi: 10.1164/rccm.201309-1634ST. Erratum in: Am J Respir Crit Care Med. 2014 Jun 15;189(12):1570. — View Citation
Vincent E, Sewell L, Wagg K, Deacon S, Williams J, Singh S. Measuring a change in self-efficacy following pulmonary rehabilitation: an evaluation of the PRAISE tool. Chest. 2011 Dec;140(6):1534-1539. doi: 10.1378/chest.10-2649. Epub 2011 Jul 7. — View Citation
VLACHOPOULOS, S. P.; NTOUMANIS, N.; SMITH, A. L. The Basic Psychological Needs in Exercise Scale: Translation and evidence for cross-cultural validity. International Journal of Sport and Exercise Psychology, v. 8, p. 394-412, 2010.
Wigal JK, Creer TL, Kotses H. The COPD Self-Efficacy Scale. Chest. 1991 May;99(5):1193-6. — View Citation
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. — View Citation
* Note: There are 24 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Physical activity in daily life | Change in physical activity in daily life monitoring by accelerometry | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Primary | Morbidity | Relationship of changes in outcomes with exacerbation, hospitalization and death | Every month after the PRP up to 24 months | |
Primary | Mortality | Relationship of changes in outcomes with death | Every month after the PRP up to 24 months | |
Secondary | Dyspnea | modified Medical Research Council (mMRC) scale. The scale range is from 0 to 5, being that higher values correspond to worse dyspnea | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Health status - COPD Assessment Test (CAT) | The CAT questionnaire range is from 0 to 40 points (8 items that range from 0 to 5 points each), being that higher values correspond to worse health status | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Health status - Saint George Respiratory questionnaire (SGRQ) | The SGRQ range is from 0 to 100% (total and three domains: symptoms, activity and impact), being that higher values correspond to worse quality of life | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Anxiety and depression symptoms - Hospital Anxiety and Depression Scale (HADS) | The HADS range is from 0 to 42 points (two domains: anxiety and depression - 21 points each), being that higher values correspond to more symptoms | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Functional status - Glittre-ADL Test (TGlittre) | Change in TGlittre | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Functional status - Six-Minute Walk Test (6MWT) | Change in 6MWT | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Functional status - London Chest Activity of Daily Living (LCADL) | Change in LCADL. The total score of LCADL (LCADLtotal) range is from 0 to 75 points and the percentage of total score of LCADL (LCADL%total) is calculated by excluding the questions answered zero. As higher the LCADLtotal and LCADL%total scores, worse the functional status | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Postural balance - force platform NeuroCom (COP) | Change center of pressure (COP) displacement | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Postural balance - force platform NeuroCom (COG) | Change in center of gravity (COG) displacement | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Postural balance -Timed Up and Go (TUG) Test | Change in TUG Test | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Postural balance - Berg Balance Scale (BBS) | Change in BBS. The scale presents 14 tasks, being that the score range is from 0 to 56 points (from 0 to 4 for each task). As lower the score, worse the postural control | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Postural balance - Activities-specific Balance Confidence (ABC) | Change in ABC. The scale range is from 0 to 1600% (16 items which range from 0 to 100% each), being that as higher the score, higher the confidence | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Postural balance - Falls Efficacy Scale - International - Brasil (FES-I-Brasil) | Change in FES-I-Brasil. The scale range is from 0 to 64 (16 items which range from 0 to 4 points each), being that as higher the score, higher the worries about falls | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Peripheral muscle oxygenation during exercise and activities of daily living (oxyhemoglobin) | Change in oxyhemoglobin of NIRS PortaMon | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Peripheral muscle oxygenation during exercise and activities of daily living (deoxyhemoglobin) | Change in deoxyhemoglobin of NIRS PortaMon | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Peripheral muscle oxygenation during exercise and activities of daily living (total hemoglobin) | Change in total hemoglobin of NIRS PortaMon | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Peripheral muscle oxygenation during exercise and activities of daily living | Change tissue saturation index of NIRS PortaMon | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Motivation - Amotivation | Change in amotivation to exercise practice will be assessed by the Behavioural Regulation in Exercise Questionnaire-2 (BREQ-2). Amotivation is scored with the sum of items 5,9,12,19 divided by 4. The score ranges between 0-4 (units on a scale). The higher the score, the greater the amotivation to exercise. | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Motivation - External regulation | Change in external regulation to exercise practice will be assessed by the Behavioural Regulation in Exercise Questionnaire-2 (BREQ-2). External regulation is scored with the sum of items 1,6,11,16 divided by 4. The score ranges between 0-4 (units on a scale). The higher the score, the greater the external regulation to exercise. | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Motivation - Identified regulation | Change in identified regulation to exercise practice will be assessed by the Behavioural Regulation in Exercise Questionnaire-2 (BREQ-2). Identified regulation is scored with the sum of items 3,8,14,17 divided by 4. The score ranges between 0-4 (units on a scale). The higher the score, the greater the identified regulation to exercise. | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Motivation - Introjected regulation | Change in introjected regulation to exercise practice will be assessed by the Behavioural Regulation in Exercise Questionnaire-2 (BREQ-2). Introjected regulation is scored with the sum of items 2,7,13 divided by 3. The score ranges between 0-4 (units on a scale). The higher the score, the greater the external introjected regulation to exercise. | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Motivation - Intrinsic regulation | Change in intrinsic regulation to exercise practice will be assessed by the Behavioural Regulation in Exercise Questionnaire-2 (BREQ-2). Intrinsic regulation is scored with the sum of items 3,8,14,17 divided by 4. The score ranges between 0-4 (units on a scale). The higher the score, the greater the intrinsic regulation to exercise. | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Motivation - Self determination | Change in self determination to exercise practice will be assessed by the Behavioural Regulation in Exercise Questionnaire-2 (BREQ-2). Self-determination index (SDI) will be scored based on the equation: [(-3x amotivation)+(-2x external regulation)+(-1x introjected regulation)+(2x identified regulation)+(3x intrinsic regulation). It ranges between -24 (lowest SDI) to 20 (highest SDI). The higher the SDI score, the greater the motivation to exercise. | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | General Self-efficacy | Change in general self-efficacy to exercise assessed by the General self-efficacy scale. The score varies from 10 to 40. The higher the score, the greater the self-efficacy | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Disease-specific self-efficacy | Change in disease-specific self-efficacy to exercise assessed by the COPD self-efficacy scale. The score ranges from 34 to 170 points. It can be also presented by a mean of the 34 items (sum of the items divided for 34). The higher the score, the greater the self-efficacy for both scales. | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Pulmonary Rehabilitation self-efficacy | Change in pulmonary-rehabilitation related self-efficacy to exercise assessed by the Pulmonary Rehabilitation Adapted Index of Self-Efficacy (PRAISE). The score range comprises a score of 15 to 60, with higher scores indicating high levels of self-efficacy | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP | |
Secondary | Basic Psychological Needs | Change in basic psychological needs assessed by the Basic Psychological Needs in Exercise Scale (BPNES). The domains scores (autonomy, competence and relatedness) varies from 4 to 20. The higher the score, the greater the fulfillment of basic psychological needs. | baseline, post-24 sessions of PRP, six months post-PRP, 12 months post-PRP and 24 months post-PRP |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|